RecruitingNot ApplicableNCT07204756

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring


Sponsor

University of Minnesota

Enrollment

400 participants

Start Date

Jan 7, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • years or older
  • Discharged after delivery at University of Minnesota Medical Center
  • Enrolled into the HOPE-BP Program

Exclusion Criteria3

  • Ongoing antihypertensive medication use at 2 weeks (time of randomization)
  • Have a medical comorbidity that would not be clinically appropriate to randomize
  • Patients opted out of clinical research

Interventions

DIAGNOSTIC_TEST2-Week Home Monitoring

Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.

DIAGNOSTIC_TEST6-Week Home Monitoring

HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.


Locations(1)

University of Minnesota

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07204756


Related Trials